Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function

(2015) Wendy E. Boertien et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Mechanisms of tolvaptan-induced toxicity in HepG2 cells

(2015) Yuanfeng Wu et al.   BIOCHEMICAL PHARMACOLOGY

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

(2015) Paul B. Watkins et al.   DRUG SAFETY

Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid–Mediated Troglitazone Hepatotoxicity

(2014) K Yang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges

(2014) John R. Senior   DRUG SAFETY

Tolvaptan for the treatment of liver cirrhosis oedema

(2014) Isao Sakaida   Expert Review of Gastroenterology & Hepatology

Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury

(2014) Jeffrey L. Woodhead et al.   Frontiers in Pharmacology

Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions

(2014) Purav Bhatt et al.   Journal of Clinical Medicine

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

(2013) Susan E. Shoaf et al.   KIDNEY INTERNATIONAL

A Multifactorial Approach to Hepatobiliary Transporter Assessment Enables Improved Therapeutic Compound Development

(2013) Ryan E. Morgan et al.   TOXICOLOGICAL SCIENCES

A membrane vesicle-based assay to enable prediction of human biliary excretion

(2013) Federico Colombo et al.   XENOBIOTICA

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

(2012) Vicente E. Torres et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endogenous bile acid disposition in rat and human sandwich-cultured hepatocytes

(2012) Tracy L. Marion et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

(2011) Susan E. Shoaf et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Sustained Volume Overload despite the Use of Conventional Diuretics: A Phase III Open-Label Study

(2011) Masatake Fukunami et al.   CARDIOVASCULAR DRUGS AND THERAPY

Pharmacokinetics, Pharmacodynamics and Safety of Tolvaptan, A Novel, Oral, Selective Nonpeptide AVP V2-receptor Antagonist: Results of Single- and Multiple-Dose Studies in Healthy Japanese Male Volunteers

(2011) Seong Ryul Kim et al.   CARDIOVASCULAR DRUGS AND THERAPY

Nonclinical Safety Profile of Tolvaptan

(2011) Akihide Oi et al.   CARDIOVASCULAR DRUGS AND THERAPY

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience

(2011) E. Higashihara et al.   Clinical Journal of the American Society of Nephrology

Drug-induced cholestasis

(2011) Manmeet S. Padda et al.   HEPATOLOGY

Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signali

(2011) Jin Chai et al.   HEPATOLOGY

Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects

(2011) Susan E. Shoaf et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Sandwich-cultured hepatocytes: anin vitromodel to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity

(2010) Brandon Swift* et al.   DRUG METABOLISM REVIEWS

Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development

(2010) Ryan E. Morgan et al.   TOXICOLOGICAL SCIENCES

New molecular insights into the mechanisms of cholestasis

(2009) Martin Wagner et al.   JOURNAL OF HEPATOLOGY

Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714

(2009) Bo Feng et al.   TOXICOLOGICAL SCIENCES

Bile-acid-induced cell injury and protection

(2009) Maria J Perez et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics

(2008) A. F. Hofmann et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process

(2008) Shiew-Mei Huang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Absence of glycochenodeoxycholic acid (GCDCA) in human bile is an indication of cholestasis: A1H MRS study

(2008) Omkar B. Ijare et al.   NMR IN BIOMEDICINE

Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis

(2007) S Teng et al.   BRITISH JOURNAL OF PHARMACOLOGY